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SUMMARY OF THE THESIS 
 
The prevalence of obesity has risen dramatically worldwide and has reached epidemic 
proportions. Particularly, visceral or abdominal obesity has been shown to correlate strongly 
with a number of pathologies, such as type 2 diabetes mellitus, cardiovascular disease and 
stroke. Consumption of fish and marine oils containing omega-3 polyunsaturated fatty acids 
(n-3 PUFAs) has been shown to be beneficial in some of these conditions. Oil from the 
marine zooplankton Calanus finmarchicus (Calanus oil) has recently emerged as a nutritional 
supplement for the human market, and the aim of this thesis was to provide data on the 
chemistry, safety issues, as well as on the physiological effects of this oil in obese rodents.  
Unlike other n-3 PUFA-rich nutritional supplements, Calanus oil is mainly composed of 
monoesters of long-chain fatty acids and fatty alcohols, also called wax esters. In addition, it 
is rich in the potent anti-oxidant astaxanthin. The fatty acid moiety of the wax esters includes 
high amounts of n-3 PUFAs (EPA, 20:5; DHA, 22:6, stearidonic acid=SDA, 18:4), as well as 
monounsaturated fatty acids (MUFAs), such as gondoic (20:1 n-9) and cetoleic acid (22:1 n-
11). Toxicology analysis confirms low levels of heavy metals, organic and non-organic 
impurities. Calanus oil supplementation (1.5%, w/w) had no adverse effects during high-fat 
feeding in rats or mice. On the contrary, it provided beneficial health effects compared to 
animals fed a high-fat diet alone, as demonstrated by (1) reduced body weight gain, (2) 
reduced deposition of intra-abdominal fat, (3) reduced adipose tissue inflammation, (4) 
reduced hepatic steatosis and (5) improved glucose tolerance. Almost identical effects were 
seen after supplementation with Calanus oil-derived wax esters (1%, w/w). Wax ester 
supplementation also improved aerobic capacity compared to high-fat diet alone. By 
comparison, supplementation with purified EPA+DHA ethyl esters in a concentration 
corresponding to the total amount of n-3 PUFAs in the wax ester diet showed primarily anti-
inflammatory effects, whereas the impact on obesity and glucose tolerance was only modest. 
In summary, Calanus oil as a dietary supplement is well tolerated and exerts beneficial effects 
against obesity and obesity-related disorders in rodents. Although the biologically active 
components are not identified, they seem to be confined to the main lipid fraction (wax esters) 
of the oil. Most likely, its beneficial effects are dependent on an interaction between different 
MUFAs and PUFAs, as well as on a rather slow digestion and uptake into the circulation at 
the distal part of the intestine. Calanus oil seems to be a good alternative to other n-3 PUFA 
containing supplements, but has the advantage of being naturally low in environmental 









1.1 Obesity and obesity-related disease 
 
The prevalence of obesity has increased dramatically world-wide during the past 2-3 decades, 
not only in industrialized
1
, but also in developing countries adopting Western life-style and 
food habits 
2
. There are no indications that the present obesity pandemic is under control or 
indications that it will change to the better.  
Obesity has a number of consequences for human health, such as insulin resistance, type 2 
diabetes, cardiovascular disease, stroke, and early, sudden death 
3
.  Clustering of a number of 
cardiovascular risk factors in obese humans is often seen and has resulted in different terms 
such as  “metabolic syndrome” 
4, 5
 “multiple risk factor clustering syndrome” 
6
 or simply 
called “cardiometabolic risk”, including the components insulin resistance, hypertension, 
hypertriglyceridemia, reduced HDL-cholesterol and increased abdominal obesity. Many of the 
risk factors occurring in these conditions can be reduced by weight loss. Excess fat around 
intra-abdominal organs, referred to as visceral or (intra-) abdominal obesity, represents a 
greater risk factor for mortality and morbidity in humans than general obesity 
7
, and 
abdominally obese individuals are particularly prone to developing diabetes 
1
. Japan has 
addressed the importance of visceral adiposity to the metabolic syndrome by prioritizing 




The increased cardiometabolic risk of excess visceral fat is most probably due to differences 
in physiological, biochemical and molecular properties of visceral and subcutaneous adipose 
tissue. For example, compared to adipocytes from subcutaneous fat depots, visceral 
adipocytes have been shown to have a higher lipolytic response to catecholamines 
9
, to be less 
responsive to insulin 
10, 11
 and having reduced expression of the anti-diabetic and anti-
inflammatory hormone adiponectin 
12




1.2 Inflammation and insulin resistance  
 
Abdominal obesity is strongly associated with insulin resistance, a condition that, if not 
halted, ultimately leads to fully developed type 2 diabetes. The mechanisms of insulin 




inflammation, especially locally in abdominal adipose tissue, together with a constant nutrient 
excess play the key role. 
The usual series of events in the case of inflammation are initiation (by infection, trauma etc.) 
followed by an immune response (infiltration of neutrophils, macrophages and other 
components of the immune system), and ultimately resolution of inflammation (Figure 1). 
While previously considered a passive event, it has now become evident that active processes 
steer the resolution process. This has led to intensified research in the field of pro-resolving 
agents 
14
. If the triggering event is not removed, such as nutrient excess in adiposity, and pro-
resolving factors are not sufficient to terminate the inflammation, a persistent (low-grade) 
inflammation develops (Figure 1). To emphasize the special etiology of inflammation in 






Figure 1. Course of acute vs. chronic inflammation. A trigger causes inflammation with the recruitment of pro-
inflammatory cells and mediators, summarized as “immune response”. Pro-resolving factors antagonize the 
immune response actively and, if their action is sufficient, it results in complete resolution (upper pathway). If 
not, the immune response is blunted but not removed, and a low-grade inflammation persists (lower pathway). 
 
Obesity leads to enlarged abdominal adipose tissue, in which a local inflammatory response is 
initiated, including increased production of pro-inflammatory cytokines (i.e. TNF-α, IL-6 and 
IL-1β) and chemokines, such as monocyte chemoattractant protein-1 (MCP-1).  
There is an ongoing debate regarding the triggering event for inflammation in adipose tissue, 






Reduced tissue pO2 has been measured in adipose tissue of both obese animals 
18
 and humans 
19
 and different explanations exist. As adipose tissue expands, it does so primarily by 
hypertrophy, i.e. an increase in size of the individual adipocytes. Hypertrophic cells lead to 
insufficient oxygen diffusion, due to increased distances between the blood-bearing vessels 
20
, 
which in turn results in local hypoxia. Other possible causal factors of adipose tissue hypoxia 
include reduced blood flow, reduction of capillary density and/or increased vasoconstriction 




The release of pro-inflammatory markers and chemokines increases the amount of 
macrophages (and other inflammatory cells) in the adipose tissue, mainly by recruitment of 
new macrophages by MCP-1. Macrophages that are usually present in the adipose tissue 
switch from an anti-inflammatory (M2) state to a pro-inflammatory (M1) state, thereby 
potentiating the inflammatory process 
21
. Dead adipocytes get surrounded by M1-type-
macrophages and form so-called "crown-like structures" (CLS), a typical picture in immune-




Nutrient excess and quality can modulate inflammation and insulin sensitivity directly or 
indirectly (Figure 2); Nutrient metabolites, such as lipid intermediates, can provoke pro-
inflammatory pathways, e.g. via toll-like receptors 
15
, but also directly impair insulin 
signaling 
16, 23
.  Inflammation, in turn can increase lipid intermediates by increasing lipolysis, 
thereby potentiating the negative influence on insulin signaling. 
 
Recently, obesity and nutrient quality have also been linked to certain gut microbiota 
phenotypes 
24
. Interestingly, obese/high fat-fed animals have a constantly higher intestinal 
permeability, while at the same time showing higher serum levels of the bacterial endotoxin 





Hypoxia and nutrient excess are also suspected to be triggers of endoplasmatic reticulum (ER) 
stress, also called “unfolded protein response”- UPR. The ER is not only involved in protein 
synthesis and folding, but also functions as a lipid and nutrient sensor. ER stress is an 
adaptive mechanism, but can ultimately lead to cell death if the underlying trigger is not 








A local inflammatory response has also been shown in the liver, contributing to increased 
gluconeogenesis and thereby to worsening of hyperglycemia. In addition, inflammatory 
mediators such as cytokines and acute phase proteins produced by the liver are contributing 
factors to systemic inflammation. Taken together, whatever the trigger and wherever the 







Figure 2. Relationship between obesity, inflammation and insulin resistance. In adipose tissue, obesity leads to 
constant nutrient excess as well as local hypoxia. Both factors can induce inflammation, either directly or via ER 
stress. Lipid intermediates such as diacylglycerol (DAG) or ceramides, resulting from increased fatty acid (FA) 
levels, can increase inflammation. On the other hand, inflammation can increase lipid intermediates by increased 
lipolysis. Inflammation and lipid intermediates can directly interfere with insulin signaling and finally lead to 







1.3  Measures against the obesity epidemic 
 
Lifestyle interventions, such as increased exercise and calorie-reduced diets, are undoubtedly 
effective in reducing obesity. Unfortunately, the long-term success rate of these interventions 
is very poor. Interestingly, change of food patterns, e.g. increased intake of less refined 
carbohydrates, are shown to have beneficial effects on cardiometabolic risk factors, 
independent of weight loss
30
. This has contributed to a change of focus from pure quantity to 
quality, and to the development of the “neutraceutical” and “functional food”-industry 
31, 32
. 
One of the emerging research fields over the past years is that of marine products with 
potential health benefits. 
 
1.4  Nutrition and fatty acid classes 
 
It has long been known that a high intake of saturated as well as trans-fatty acids is harmful, 
especially for cardiovascular health, and their replacement by mono- and polyunsaturated 
fatty acids (MUFAs and PUFAs, respectively) has been implicated in recommendations from 
institutions like the American Heart Association
33
. However, it has become evident that a 
generalization of PUFAs is inadequate due to the different biological mechanism of its 
subclasses as discussed in the following. 
 
1.4.1  Polyunsaturated fatty acids (PUFAs) 
 
The two main classes of PUFAs are the omega-3 and omega-6 polyunsaturated fatty acids (n-
3 PUFAs and n-6 PUFAs, respectively). The ratio of n-6 to n-3 PUFAs in our diet has risen 
from close to 1:1 in the times of hunters and food-gatherers to today’s values of 15-20:1  
34
. 
There is considerable evidence showing that a high content of n-6 PUFAs in the diet, relative 
to n-3 PUFAs, is a predisposing factor for obesity 
35
, and very recently an updated meta-





Replacing n-6 by n-3 PUFAs or simply increasing the intake of n-3 PUFAs in the diet has 
proven to be beneficial, resulting in recommendations of a n-6/n-3 ratio of 4:1 to5:1
37
. Most 
research on n-3 PUFAs has been done on eicosapentaenoic acid (EPA; 20:5 n-3) and 




the plant-derived alpha-linolenic acid (ALA; 18:3 n-3), which is the common precursor for 
EPA and DHA, is a widely investigated n-3 PUFA. n-3 and n-6 PUFAs share the same 
enzymes involved in the metabolic pathway for conversion of these fatty acids (see Figure 3). 
Therefore, excess of one fatty acid family can interfere with the metabolism of the other, 
significantly reducing its conversion and thereby the biologic action of the metabolite(s). n-3 
PUFAs have potent anti-inflammatory effects. Accordingly, n-3 PUFA supplementation has 
been proven to be beneficial in different pathologies like cardiovascular disease, rheumatoid 
arthritis, diabetes mellitus and neurological diseases, many of which are related to 
inflammation. One of the suggested underlying mechanisms for the anti-inflammatory effects 
is the reduction of the n-6 PUFA arachidonic acid (AA; 20:4 n-6) via substrate competition. 
Since AA is correlated with a high pro-inflammatory activity, due to its potential to generate 
pro-inflammatory eicosanoids (prostaglandins, leukotrienes, thromboxanes etc; Figure 3) 
38, 39
, 
its reduction implies decreased inflammation.  
Other suggested mechanisms behind n-3 PUFA-mediated reduction in inflammatory activity 
include inhibition of the pro-inflammatory NFkB signalling pathway, increased production of 
pro-resolving mediators (such as resolvins, protectins or maresins) 
40
 and activation of the 




Resolvins, protectins and maresins are newly emerged families of mediators derived from 
EPA and DHA, which are potent in very low concentrations (pg-ng) 
43
. GPR 120 is a recently 





, but also in the intestine 
41, 45
, especially in entero-endocrine 
cells 
45, 46
. GPR 120 has been shown to exert anti-diabetic and anti-inflammatory actions 
41
. 
Taken together, different mechanisms of action, both via anti-inflammatory mechanisms (i.e. 
reduction of AA-derivates and GPR 120-activation) as well as via the pro-resolving axis can 







Figure 3. Simplified metabolic pathway for conversion of n-6 and n-3 polyunsaturated fatty acids (PUFAs), 
rendering predominantly pro-inflammatory mediators derived from n-6 PUFAs (left hand side) and pro-resolving 
(thereby indirectly anti-inflammatory) mediators derived from n-3 PUFAs (right hand side). Cyclooxigenases 
(COX) and lipoxigenases (LOX) catalyze the production of these mediators. Resolvins are named after the initial 
letter of their precursor n-3 PUFA: E-series for eicosapentaenoic acid (EPA)-derived, D-series for 
docosahexaenoic acid (DHA)-derived resolvins. AA=arachidonic acid, SDA=stearidonic acid 
 
Even though the human body can synthesize EPA and DHA from its precursor ALA, the 





Therefore, direct supplementation with EPA and/or DHA is the preferential mode of 
increasing incorporation of these beneficial PUFAs in human tissue, but intake in the general 
population is often far below recommended levels 
48
. Stearidonic acid (SDA; 18:4 n-3), the 
first metabolite formed directly from ALA by the rate-limiting enzyme ∆
6
desaturase, is an 
alternative for oral n-3 PUFA substitution
48
. It is rapidly and more efficiently than ALA 
converted into longer n-3 PUFAs 
49-51
and has been shown to successfully increase the so-
called “omega-3 index” 
52
. This index is a surrogate measure for the incorporation of EPA and 
DHA in tissues and can be considered as a cardiovascular risk marker, as tissue incorporation 




1.4.2  Monounsaturated fatty acids (MUFAs)   
 
Since the “Seven Countries study” first pointed out the diet from the Mediterranean region as 
beneficial for the reduction of cardiovascular risk 
54
, a lot of research has been done on 




percentage of the MUFA oleic acid (18:1 n-9). Therefore, researchers have proposed an 
important role of MUFA for cardiovascular health. In fact, MUFAs are reported to have 
favorable effects on metabolic syndrome and markers of cardiovascular disease risk such as 
blood pressure, blood lipids and insulin sensitivity, as well as the potential to ameliorate 
obesity risk 
55
.  The focus of MUFA research has mainly been on oleic acid, whereas others, 
i.e. gondoic (20:1 n-9) or cetoleic acid (22:1 n-11), have hardly been investigated, despite 
their relative abundance in some fish types. However, these two long-chain marine-derived 
MUFAs are of great interest, as recent studies by a Japanese group have shown beneficial 




1.5  Calanus oil and wax esters 
 
The marine zooplankton Calanus finmarchicus, a member of the copepod-family, is the most 
abundant crustacean and one of the dominating food sources for fish in the North Atlantic 
59
. 
The annual biomass production is enormous, and, as only a minor fraction of it is being 
utilized by fish and sea mammals 
60
, vast amounts are available for direct harvesting, 
representing a novel raw material for the Norwegian biomarine industry. Calanus 
finmarchicus is feeding on phytoplankton and stores energy mainly as oil, which makes up to 
50 % of its dry weight 
61
. As Calanus finmarchicus is situated at a low trophic level of the 
marine ecosystem, Calanus oil contains very low, if any, levels of environmental pollutants 




Calanus oil is rich in the same n-3 PUFAs as those found in other marine oils - EPA and DHA 
– but contains in addition high amounts of SDA as well as other long-chain FA such as the 
MUFA gondoic acid (20:1 n-9) and cetoleic acid (22:1 n-11) 
63, 64
 .   
With only a few exceptions, those fatty acids (FAs) are not found, or found in small quantities 
in other marine oils. The exact percentages of FA-contents are difficult to predict as they 
fluctuate with time point and location of harvesting 
61, 65
. Table 1 shows the composition of 






Table 1. Concentrations of the main components of Calanus oil. Saturated fatty acids (SFA), monounsaturated 
fatty acids (MUFA), polyunsaturated fatty acids (PUFA), fatty alcohols (FAOH) 
 
While the FAs in fish and marine mammals are mostly bound as triacylglycerol, they are 
found primarily in phospholipids in Antarctic krill (Euphasia superba). In Calanus 
finmarchicus, on the other hand, the majority of the FAs (about 80%) is esterified to 
unsaturated fatty alcohols as so-called wax-esters. 
 
Wax esters in general are FAs esterified to fatty alcohols (FAOHs). In copepods such as 
Calanus finmarchicus, wax esters represent a long-term energy storage and regulate buoyancy 
66
. In Calanus oil, the FAs have a carbon chain length ranging from 14-22, including both 
saturated fatty acids (SFAs), MUFAs and PUFAs. The FAOHs are mostly monounsaturated 
with a carbon chain length of 16-22 
67







Figure 4. A typical wax ester in Calanus oil with the polyunsaturated omega-3 fatty acid SDA (18:4 n-3) and a 





Apart from its high amount of wax ester-bound unsaturated fatty acids, Calanus oil contains a 
number of other components, including phytosterols and anti-oxidants such as astaxanthin. 
Phytosterols have been approved by both American and European Food safety authorities as 
cholesterol-lowering food additives in margarines 
68, 69
 
The carotenoid astaxanthin is one of the strongest anti-oxidants found in nature 
70
, providing 
protection of stored lipids both in Calanus finmarchicus and other copepods 71. Astaxanthin 
has been attributed potential health benefits in a number of diseases, such as cancer, chronic 








2. AIM OF THE STUDY 
 
Despite its high content of potentially health-promoting compounds and its enourmous 
biomass in the North Atlantic, Calanus finmarchicus has not been investigated for its possible 
health effects until recently;  Eilertsen et al.
73
 showed that Calanus oil supplementation 
decreased plaque formation in the aorta of apoE-deficient mice. Beyond that, no health-
promoting effects of Calanus oil have been reported in the literature.  
Given the rising prevalence of obesity and obesity-related disorders, the aim of this study was 
to investigate the effect of Calanus oil on diet-induced obesity and its metabolic disorders. As 
the wax ester-binding of fatty acids is a unique feature that distinguishes Calanus oil from 
other marine oils, the study was also designed to examine the role of Calanus oil-derived wax 
esters. Furthermore, in the light of a potential use as a health supplement for humans, data on 





3. METHODOLOGICAL CONSIDERATIONS 
 
3.1  Animal studies 
 
In this study we used Wistar rats and C57Bl/6 mice. C57Bl/6 mice are the best characterized 
inbred mouse strain, and it is widely used in high fat-feeding studies, as these animals are 
highly prone to diet-induced obesity (DIO) and diabetes. In line with many other groups (and 
commercially available DIO mice) we used the so-called “van Heek-series” diets 
74
. The lard-
based high-fat diet (HFD) contained 45% energy from fat (Test diet 58V8, corresponding to 
the original D12451 from Research Diets) and was used for both our diet-induced overweight 
controls (HFD) and as the basis for the substituted diets. Even though the diet is called “high-
fat”, it also has a considerable amount of carbohydrates (36 energy%), especially in the form 
of sucrose, thus being closer to the typical obesogenic “Western” diet than other widely used 
high-fat diets, such as those in which 60% energy is derived from fat. The specification sheet 
of the high-fat base diet is shown in the Appendix. 
 
3.2  The working heart method and cardiac substrate 
utilization 
 
Cardiac effects of Calanus oil supplementation were investigated in isolated rat hearts; 
Functional parameters and myocardial substrate utilization were assessed in the isolated 
perfused working heart model (Figure 5). In this ex vivo model, the heart is removed from its 
natural milieu and therefore will not reflect the complete in situ characteristics of the heart 
75
.  
However, the working heart model has become an important tool for characterizing cardiac 
phenotype in animal models, allowing assessment of both heart function and metabolism in 





       
Figure 5. Experimental set-up of the Working Heart Model. Perfusate: Krebs-Henseleit-Bicarbonate buffer 
contained 200 µmol/L albumin-bound palmitate and 11.1 mmol/L glucose. RV=right ventricle, LV=left 
ventricle, LA=left atrium 
 
The main substrates used by the heart are fatty acids (FAs) and glucose, and their relative 
contribution to the energy (ATP) production is regulated by the substrate availability 
according to the “glucose-fatty acid-cycle”, also known as the Randle cycle 
76
. When plasma 
levels of circulating FAs are high, such as in the diabetic or pre-diabetic state, myocardial FA 





In our experiments, myocardial substrate metabolism was assessed by adding trace amounts of 
radioactively labeled glucose ([U-
14
C]-glucose) and palmitate ([9,10-
3
H]-palmitate) to the 






3.3  Glucose tolerance test 
 
Glucose tolerance was assessed by an intraperitoneal glucose tolerance test (IPGTT).  
Oral glucose tolerance tests (OGTTs) are more physiological and, due to increased incretin 
secretion following elevated enteral glucose concentrations, differences in glucose tolerance 
between groups might be easier revealed via OGTTs than IPGTTs 
79, 80
. However, the IPGTT 
is still a good, widely used, and not at least easily applied method of assessing glucose 
tolerance. We also find it less stressful to the animals and chose therefore to carry out IPGTT 





3.4  Intra-abdominal fat depots 
 
There is a strong association between intra-abdominal fat (also called “visceral fat”) and the 
risk for various diseases. Therefore, measurements of abdominal fat depots are cornerstones 
of studies on diet-induced obesity. There are several terms for the different fat depots inside 
the abdominal cavity of rodents. They are often, though not necessarily correctly, used 
interchangeably. Our definition of intra-abdominal fat depots in rodents includes the 
following four depots: the omental, mesenteric, perirenal (pWAT) and perigonadal fat. The 
latter is called epidydimal fat (eWAT) in males and is the most frequently reported fat depot 
in rodent obesity studies. We measured pWAT and eWAT, two depots that are distinct and 
easily identified, and can therefore be dissected out and weighed with high precision. While 
omental and mesenteric fat depots are drained via the portal vein, leading directly into the 
liver, pWAT and eWAT are drained systemically. According to the “portal theory”, increased 
non-esterified fatty acids (NEFA), and possibly cytokines from visceral fat cause hepatic 
insulin resistance 
81
. Thus it would have been desirable to also have investigated a depot that 
is drained via the portal vein. However, it has been shown that surgical removal of eWAT and 
pWAT in rats improves insulin sensitivity 
82, 83
, indicating an important metabolic role in 
rodents. Furthermore, reduction of pWAT and mesenteric fat has been shown to be fairly 
similar in young animals under caloric restriction
84
. Thus we investigated pWAT as a 
representative of the intra-abdominal fat while at the same time being aware of metabolic 
differences within intra-abdominal fat depots.  
 
3.5  Liver triacylglycerol content 
 
For the assessment of hepatic steatosis, liver triacylglycerol (TAG) content was measured by 
the method of Folch et al. 
85
. For years, increased TAG content in tissues such as liver and 
skeletal muscle has been proposed as the cause for insulin resistance. This has been 
challenged by a number of investigators, and there is now good evidence that high 
concentrations of diacylglycerols (DAG) or ceramides, rather than TAG, are causally 
connected to insulin resistance 
86
. Nevertheless, when taken as an indicator of fat 







3.6  Immunohistological investigations 
 
Identification of macrophages in our study has been done by staining with the antibody F4/80. 
It is an extracellular antigen (glycosylated proteoglycan) found on murine macrophages 
87
. 
The human equivalent to F4/80 is EMR1.  
Macrophages in adipose tissue of obese individuals are known to form so-called crown-like 
structures (CLS), surrounding dead adipocyte(s) 
22
. The presence of CLS was confirmed in 
our obese animals.  
As mentioned in the introduction, macrophages can be divided into the proinflammatory M1- 
and the anti-inflammatory M2-subpopulation. The F4/80 marker is merely a general 
macrophage marker, whereas others such as CD11c (M1) or MGL-1 (M2) can distinguish 
between the two populations 
21, 88
. Ideally we would have used one or several of those more 
specific antibodies. On the other hand, the CLS in our immunohistochemistry sections were 
very typical, and other groups have identified the macrophages in CLS to be of the M1 
population 
88
. Therefore, we are confident that the choice of the F4/80 antibody was adequate 
for our purposes. 
 
3.7  Choice of EPA/DHA preparation 
 
In paper II we compared the Calanus-derived wax ester with ethyl ester-bound EPA and 
DHA. In commercially available n-3 PUFA products, the majority of long-chain fatty acids is 
bound in three different chemical forms: triacylglycerols (fish and cod liver oil), 
phospholipids (Antarctic krill oil) or ethyl esters (EPA + DHA concentrates). Even though a 
lower bioavailability of ethyl ester-bound PUFAs compared to other preparations such as 
TAG has been discussed in humans 
89
, findings are not consistent 
90
, probably because 
absorption seems to be dependent on co-administration of fatty meals 
91
. In addition, the only 
prescription form of omega-3 fatty acids for humans is an ethyl ester preparation of EPA + 
DHA (LOVAZA/OMACOR). Most importantly for our rodent experiments is the fact that 
Gorreta et al. 
92
 found a similar bioavailability of EPA and DHA, regardless of whether n-3 
PUFAs were given as a TAG-, an ethyl ester- or a wax ester- preparation. Thus, we chose 






4. SUMMARY OF RESULTS 
 
 
Paper I: C57Bl/6 mice fed a high-fat diet (45% energy from fat) supplemented with 1.5% 
(w/w) Calanus oil showed significantly reduced body weight gain, abdominal fat and hepatic 
steatosis and improved glucose tolerance when compared to mice fed the high-fat diet alone. 
In adipose tissue, Calanus oil supplementation significantly reduced adipocyte size and it 
increased mRNA expression of adiponectin. It also significantly reduced macrophage 
infiltration, accompanied by reduced mRNA expression of pro-inflammatory cytokines 
(TNF, IL-6 and MCP-1). The effects of Calanus oil were not only preventive, but also 
therapeutic, as the oil proved to be beneficial, regardless of whether supplementation was 
started before or after the onset of obesity and glucose intolerance.  
 
Paper II: C57Bl/6 mice received a high-fat diet (HFD; 45% energy from fat) and were 
supplemented with either 1% (w/w) wax ester (WE) or 0.2% (w/w) EPA and DHA ethyl ester 
(E/D) after obesity and glucose intolerance was established. Compared to mice fed HFD 
without supplementation, WE significantly reduced body weight gain, abdominal fat and 
hepatic steatosis while improving glucose tolerance and aerobic capacity. In abdominal fat 
depots, macrophage infiltration was significantly reduced, mRNA-expression of pro-
inflammatory genes (TNF, IL-6 and MCP-1) downregulated and adiponectin expression up-
regulated. By comparison, E/D did not significantly affect any of the obesity parameters 
(body weight gain, abdominal fat or heatic steatosis) or mRNA-expression of adiponectin. It 
did, however, suppress the expression of pro-inflammatory genes and improved glucose 
tolerance, although not to the same extent as WE.  
 
Paper III: Analysis of the biochemical composition of Calanus oil revealed a very high 
percentage (>80%) of fatty acids bound as wax esters. The wax esters consist of primarily 
C20 and C22 unsaturated fatty alcohols and a variety of long-chain fatty acids. The fatty acid 
composition showed high amounts of n-3 PUFAs (mainly EPA, DHA and SDA) and MUFAs 
(mainly gondoic and cetoleic acid) present in the oil. Toxicologic analysis of Calanus oil 
demonstrates that all values for heavy metals, pesticides, organic and non-organic impurities 
either fall well below the maximum limits or at levels which do not pose a toxicological 




safe with no apparent impairment of physical status or physiological parameters, including 
blood parameters, organ weights and cardiac function. Cardiac metabolism was not affected 







5.1  General discussion 
 
This thesis shows that oil from the marine zooplankton Calanus finmarchicus has a unique 
composition of fatty acids as well as low toxicity levels. Oral supplementation with up to    
1.5 % (w/w) is well tolerated and does not seem to negatively affect physiological functions 
in rodents. On the contrary, in a concentration of 1.5% (w/w) it seems to have beneficial 
effects in diet-induced obese animals, as shown by: 
 
1) Reduced body weight gain 
2) Reduced intra-abdominal fat tissue mass 
3) Reduced inflammation in intra-abdominal fat tissue 
4) Reduced hepatic steatosis 
5) Improved glucose tolerance 
 
Supplementation with 1% Calanus oil-derived wax esters (i.e. fatty acids bound to long chain 
fatty alcohols), showed almost identical results. However, supplementation with purified 
EPA/DHA ethyl esters in a concentration similar to the total n-3 PUFA content of the Calanus 
oil/wax ester diet, did not show significant effects on parameters listed above, except for the 
anti-inflammatory effects. Figure 6 is a simplified figure showing the main findings and 






Figure 6.  Schematic overview over findings of this thesis. Effects of Calanus oil, wax esters and EPA/DHA 
ethyl esters on inflammation, glucose tolerance and obesity (including increased body weight, abdominal fat and 
hepatic fat content). This thesis shows that, while EPA/DHA supplementation mainly influences inflammation, 
supplementation with both wax esters and crude Calanus oil has beneficial effects on all parameters measured. 
 
As shown in the above illustration, the mutual interface of crude Calanus oil, purified wax 
esters and purified EPA/DHA ethyl esters was reduced inflammation, while glucose tolerance 
was only slightly affected and there was no influence on obesity parameters under EPA/DHA 
ethyl ester supplementation. Therefore, it is evident that some factor, other than n-3 PUFAs, is 
contributing to the beneficial effect of Calanus oil, especially to the reduction of body weight, 
abdominal fat and hepatic steatosis, summarized as “obesity” in the figure.  
 
The main difference to other commonly used marine oils is the high amount of wax ester-
bound fatty acids. Also, Calanus oil is rich in astaxanthin and contains considerable amounts 
of phytosterols. In animal studies, phytosterols and/or astaxanthin have been shown to have 
similar effects as Calanus oil on some of the parameters measured in our study; namely 
reduced body weight gain and abdominal fat mass 
93-96





reduced insulin levels and improved glucose metabolism 
97-99
. On the one hand, it is important 
to note that the substances in those studies were applied in much higher doses than in our 
Calanus diet. Most importantly, however, is that we found almost identical results when 
supplementing the purified wax ester fraction of Calanus oil. This extract is a pure fatty 




phytosterols or astaxanthin to the beneficial effects of Calanus oil is unlikely. The following 
discussion will therefore focus on the potential role of the wax esters and the fatty acids 
bound within. 
 
5.2 Body weight, abdominal obesity and hepatic steatosis 
  
Compared to the un-supplemented animals on a high-fat diet, both Calanus oil-fed and wax 
ester-fed animals were clearly less obese, as indicated by significantly reduced body weight 
gain, abdominal fat and hepatic steatosis. Obesity is the consequence of an imbalance of 
anabolic and catabolic processes. Mechanisms of weight/fat reduction include decreased 
energy intake, suppressed lipogenesis, combined with increased lipolysis and fatty acid 
oxidation, lipid catabolism in the small intestine, reduced fat absorption and/or increased 
gastric emptying, all of which previously have been reported for n-3 PUFA supplementation 
in animals 
100-105
. In this thesis however, anti-obese effects in the EPA/DHA ethyl ester group 
were not observed. This may be related to i) the fact that we started the treatment after the 
establishment of obesity, while most studies showing beneficial effects of  n-3 PUFAs use a 
preventive rather than a therapeutic approach 
101, 106-108
, and/or  ii) the much lower 
concentration of EPA/DHA given in our diet as compared to earlier studies. Body weight 
reduction by n-3 PUFAs seems dose-dependent 
106
and the EPA/DHA concentration in our 
studies was about 7-35 times lower than in other studies 
101, 106-108
. 
Another fatty acid group which could possibly be responsible for anti-obesity effects are 
MUFAs, which are highly abundant in Calanus oil and its wax esters. Diets rich in plant-
derived MUFAs show inconsistent data in humans, but overall seem to have an either neutral 
or reducing effect on body weight gain 
55
 and they have also been shown to decrease liver fat 
and increase lipolysis 
109-111
. Interestingly, in a recent study on obese and diabetic mice, 
supplementing a MUFA-rich marine oil, leads to similar results as in our study 
57
, indicating a 
role of MUFAs in obesity and obesity-related disorders. 
 
5.3  Inflammation and glucose metabolism 
 
We showed that Calanus oil and its wax esters attenuated a local inflammatory response in 
abdominal adipose tissue, including reduced adipocyte size, inflammatory gene expression 




was increased, glucose and insulin levels were lowered and glucose tolerance improved. As 
local pro-inflammatory mediators can create a systemic inflammation that adversely affects 
metabolic function 
15
, improved glucose tolerance in Calanus oil/wax ester-supplemented 
obese mice could, at least in part, be explained in terms of the simultaneous reduction of the 
inflammatory status.  
Pro-inflammatory cytokines can also downregulate the adipocyte-derived hormone 
adiponectin 
112
, known for its insulin-sensitizing properties. Consequently, by a reduction in 
inflammation, adiponectin expression can be recovered, which in turn could improve glucose 
tolerance. Interestingly, though, despite the adipocyte-reducing and anti-inflammatory effect 
of the EPA/DHA diet, adiponectin expression was not altered and glucose tolerance was less 
improved in EPA/DHA-fed animals compared to the wax ester-fed animals. In contrast to our 
findings, adiponectin has been shown to be upregulated by n-3 PUFAs 
113-115
. The reason for 
this discrepancy could be due to the extremely low concentration of EPA/DHA in our diet as 
compared to that of previous studies 
113-115
, or it may be related to the the lack of obesity-









. Yang et al. has done feeding studies with MUFA-rich fish-
oils from saury (Colocabis saira) 
57
 and pollock (Theragra chalcogramma) 
119
, showing 
results similar to ours, such as reduction of  abdominal fat 
57
, reduced hepatic steatosis 
119
 as 
well as improvement in glucose homeostasis
57
 and increased adiponectin
57, 119
. These oils are 
rich in gondoic and cetoleic acid, but their content of EPA and DHA is also relatively high. A 
beneficial additive effect or synergism of MUFAs and PUFAs in those oils is highly 
plausible, and this could also be suspected for Calanus oil and its wax esters.  
Unfortunately, Yang et al.
57, 119
 did not show the fat classes of the oils used. However, Ota et 
al. 
120
 showed that, despite feeding mainly on copepod species, the dominating fat classes of 
Pacific saury are TAG, NEFA and phospholipids, while the wax ester content is minimal. In 
Calanus oil, on the other hand, wax ester-bound FA comprise over 80% of the oil.  
It should again be noted that the oils in the studies of Yang et al.
57, 119
 were applied at a much 
higher dose than the Calanus oil in the present feeding studies. So the question remains how 
we could obtain similar effects with a much lower concentration. 
Recently, products from Antarctic krill (Euphasia superba), containing high amounts of EPA 
and DHA, but also anti-oxidants like astaxanthin, have emerged as a possibly health-




which has been suggested to be the reason for the apparently superior effect of krill compared 
to fish-oil products 
121, 122
. Interestingly, in recent studies, krill oil supplementation in obese 






), but they were also achieved with relatively low doses. 
Concentrations of EPA and DHA were only about 2-3 times higher than in our diets, hence 
well below concentrations used in other fish-oil studies.  
Taken together, even though a synergistic effect of MUFAs and PUFAs is highly possible in 
the case of Calanus oil/wax ester-mediated health effects, the type of fatty acid binding within  
the oil could also be of importance. 
 
5.4. Wax esters 
 
Although part of the human diet for centuries 
126
, little has been investigated in terms of 
beneficial health effects of wax esters; A cholesterol-lowering effect is suggested for plant-
derived wax esters 
126
, whereas marine wax esters have gained a rather negative reputation 
due to outbreaks of so-called “keriorrhea” –an oily discharge from the rectum following 
ingestion of wax ester-rich fish 
127, 128
. This phenomenon lead to the assumption that 
mammals cannot digest wax ester. However, there is good evidence that mammals can digest 
wax esters, at least to a certain degree 
92, 129-131
. At the same time, there are indications of a 




This is very interesting in the light of findings by Morishita et al. 
133
, showing that after a 
glucose challenge, secretion of glucagon-like peptide-1 (GLP-1), an insulinotropic incretin, 
was increased by delivery of DHA and EPA locally in the colon, but not in the stomach or 
proximal jejunum. The increased GLP-1 secretion resulted in a significant plasma glucose 
reduction 
133
. GLP-1 is produced by L-cells in the distal intestine (ileum and colon). Of note, 
L-cells have been reported to be co-located with GPR120, a receptor for n-3 PUFA, which has 
been shown to mediate potent anti-inflammatory and insulin-sensitizing actions, and whose 
dysfunction might be an underlying factor for diet-induced obesity 
41, 42
. It is therefore 
tempting to speculate that a delayed release of wax ester-bound n-3 PUFAs could have 
activated intestinal GPR120 and thereby contributed to the beneficial metabolic effects of wax 





Also, hydrolysis of wax esters yields fatty acids and fatty alcohols in equal parts. Long-chain 
alcohols per se have been shown to increase physical performance 
134, 135
 and exert anti-
inflammatory effects 
136
. We have access to preliminary data from studies with Calanus oil 
showing that fatty alcohols are discharged with the feces (Pedersen et al., Norwegian College 
of Fishery Science, UiT The Arctic University of Norway, unpublished results). However, as 
we do not have quantitative data on the percentage of fatty alcohol excretion, the role of fatty 
alcohols per se, regarding the beneficial effects of Calanus oil, is uncertain and requires 
further investigation. 
 
5.5. The search for “the magic bullet” 
 
In this discussion we have been focusing on the potential role of mono- and polyunsaturated 
fatty acids on beneficial health effects of Calanus oil. The question is whether it is reasonable 
trying to single out one individual active component in a natural product or diet, “dissecting” 
it into singular potentially beneficial components. One has to keep in mind that the result of a 
treatment is often the effect of several different components acting together. The single 
components could even have opposite effects, but it is the sum of all that accounts for the 
final effect.  
 
There are many examples that beneficial health effects of specific diets or natural products 
cannot solely be attributed to one single component. For example: Despite a complex micro- 
and macronutrient composition of the famous “Mediterranean diet”, authors tend to pinpoint 
MUFAs as the beneficial factor in the Mediterranean diet. This results from the widespread 
use of MUFA-rich olive oil. However, beneficial effects of olive oil cannot be reduced to the 
high MUFA content alone, but may be dependent on other components such as 
polyphenols
137
. Likewise, studies with marine oils generally ascribe their beneficial effects to 
EPA and DHA, although the composition of marine oils is often very complex. Also, fish in 




Thus, in all natural products, it is more likely that several components act in an additive or 
synergistic way rather than one being “the magic bullet”. As Hansen et al. already suggested 
almost 20 years ago, the beneficial effects of the Inuit diet it is probably a combination of 
both n-3 PUFAs and MUFAs, but also antioxidants  
139




Calanus oil. Even if it was evident from our experiments that the active compounds of 
Calanus oil are confined to the wax ester fraction, non-fatty acid components such as the anti-
oxidant astaxanthin are probably contributing, for example by limiting oxidation of fatty acids 
and thus increasing its stability and shelf life.  Also, apart from a possible favourable action 
related to activation of PUFA-recognizing receptors in the distal part of the intestine, the  
binding of fatty acids to fatty alcohols in the form of wax esters is probably an additional 
protective factor; Due to their solid or semi-solid form, wax esters present a more stable (less 
prone to oxidation) and thus more palatable form of n-3 PUFA supply 
92
.  
Although it is of commercial interest (functional food industry) to identify the active 
component(s) of Calanus oil, research to reveal the underlying physiological mechanisms by 





6. SUMMARY AND FUTURE IMPLICATIONS 
 
6.1 Summary  
 
Calanus oil as a dietary supplement is well tolerated and exerts beneficial effects against 
obesity and obesity-related disorders in rodents. Although the biologically active components 
are not identified, they seem to be confined to the main lipid fraction (wax esters) of the oil. 
Most likely, its beneficial effects are dependent on an interaction between different MUFAs 
and PUFAs, as well as on a rather slow digestion and uptake into the circulation at the distal 
part of the intestine. Calanus oil seems to be a good alternative to other n-3 PUFA containing 
supplements, but has the advantage of being naturally low in environmental contaminants and 
effective in very small amounts. 
 
6.2 Future implications 
 
Even though Calanus oil has shown beneficial health effects in obese rodents, our findings do 
not provide specific insight into the mechanistic action of the oil. The beneficial effects, 
however, seem to be related to the reduction of intra-abdominal adipose tissue, as well as 
reduced adipose tissue inflammation. Future experiments measuring whole body energy 
expenditure and motor activity are planned in our laboratory in order to explain the fat 
reducing effect of Calanus oil. Finally, it remains to be shown whether the effects of Calanus 
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